Avantor Investor Conference Presentation Deck
Biopharma offering drives half of Avantor's revenue
RESEARCH & DEVELOPMENT
MSD Growth Rate
-50% of
Biopharma
Revenue¹
Unparalleled access
- Extensive portfolio
- Onsite service associates
- Collaboration that seeds
bioproduction
Navantor™
1, FY20 estimate
CLINICAL & BIOREPOSITORY
HSD-DD Growth Rate
-15% of
Biopharma
Revenue¹
-Scale-up and clinical trial
services
- Custom kitting, packaging
- Equipment sourcing,
deployment and management
- Storage and archiving for
regulated environments
ORGANIC GROWTH $
BIOPRODUCTION
DD Growth Rate
-35% of
Biopharma
Revenue¹
-
- Collaboration to support process
optimization
- Broad range of GMP materials
- Highly characterized
chromatography resins, solutions
Robust pipeline
39th Annual J.P. Morgan Healthcare Conference
13.View entire presentation